🟢 Strong Evidence
Human organs do not age uniformly. A Stanford-led study measuring plasma proteins in 44,498 individuals identified distinct biological aging rates across 11 organ systems, with approximately one in five people showing meaningfully accelerated aging in at least one organ, according to research published in Nature Medicine (2025). The analysis reveals that brain and immune system aging dominate mortality risk, with combined youthful profiles associated with a 56% reduction in 17-year mortality.
Key takeaways
- Brain and immune system biological age are the strongest predictors of mortality risk, more influential than other nine organs studied
- Youthful brain aging at age 50 confers Alzheimer’s risk reduction equivalent to carrying APOE2/2, the most protective genetic variant
- Plasma proteomics-based organ aging clocks are currently available only on a waitlist, with broader clinical availability expected in 2027–2028
- No randomized trials yet demonstrate whether interventions can slow brain or immune organ aging in humans
Study at a Glance
| Source | Nature Medicine |
| Study type | Observational cohort analysis with proteomics biomarkers |
| Sample size | N = 44,498 |
| Population | Adults with longitudinal plasma protein measurements and mortality follow-up |
| Organ systems | 11 separate biological aging clocks: brain, immune, cardiovascular, and 8 others |
Mortality Risk Reduction by Organ Aging Profile
17-year mortality reduction (%) for combined youthful aging across organ systems, Stanford cohort (2025)
Source: Oh et al., Nature Medicine 2025 | Stanford University | Georgian Medical Journal News
Brain Aging Emerges as the Dominant Mortality Predictor
Biological age of the brain—measured through plasma protein biomarkers—predicts long-term mortality risk more strongly than chronological age or genetic risk factors, according to the Stanford team’s findings. Individuals with youthful brain biological aging at age 50 achieve Alzheimer’s disease risk reduction equivalent to carrying the APOE2/2 genotype, the most protective genetic variant known for cognitive preservation, the research published in Nature Medicine indicates.
Conversely, accelerated brain aging confers cognitive and mortality risk comparable to APOE4 carriership, a well-established genetic risk factor for Alzheimer’s disease and cardiovascular mortality. This suggests that modifiable factors affecting brain biological aging may rival or exceed genetic determinants in importance. The clinical implications extend beyond neurology: brain health emerges as a foundational pillar of longevity, not merely a neurological concern.
Immune System Aging Shows Independent Mortality Effect
The immune system’s biological age contributes independently to mortality prediction, with youthful immune aging reducing 17-year mortality by approximately 21% in univariate analysis. When combined with youthful brain aging, the protective effect rises to 56%, demonstrating synergistic benefit, according to the Stanford analysis. This additive effect—unique to the brain-immune pairing—does not occur with combinations involving the other nine organs studied.
The immune system’s role aligns with established evidence on chronic inflammation as a mortality driver. Plasma proteomics captured markers of immune senescence and systemic inflammation, systems long implicated in aging-related mortality across multiple disease pathways. The finding suggests that aging clocks capturing immune protein signatures may offer early detection for interventions targeting inflammaging, a hallmark of biological aging.
Technology Gap: Availability and Clinical Translation
The plasma proteomics-based organ aging test described in the Stanford research is not yet commercially available for routine clinical use. Currently, biological age tests available to consumers rely on DNA methylation technology, which provides a single composite aging score rather than organ-specific aging clocks. The Stanford plasma proteomics version is accessible only through Vero Bioscience on a waitlist basis, with anticipated broader clinical availability in 2027–2028, according to the source report.
This timeline gap is significant: clinicians and patients cannot yet access the 11-organ aging measurement system outside research settings. DNA methylation-based tests, while commercially available, measure a different biological process (epigenetic changes rather than circulating protein signatures) and do not provide the organ-specific granularity demonstrated by the Stanford team. Patients seeking biological age assessment should understand this distinction when evaluating available commercial offerings.
Causality Remains Unproven—Randomized Evidence Still Needed
The Stanford study is observational in design: it measures associations between plasma protein signatures and mortality, but does not establish whether slowing brain or immune aging can reduce mortality in humans. No randomized controlled trial has yet tested interventions designed to reverse or slow these biological aging processes in people. This is a critical distinction: while the data strongly suggest that brain and immune aging matter, proof that modifying them improves outcomes awaits intervention trials.
The research does point to modifiable candidates for investigation. Sleep quality, regular physical exercise, social engagement, and management of chronic inflammation have been associated with better health outcomes and may influence biological aging markers. However, the Stanford proteomics study cannot confirm whether these factors causally alter brain or immune aging—only that younger biological age in these systems associates with lower mortality. Future clinical trials will be necessary to move from association to causation and to establish whether interventions targeting these pathways improve real-world outcomes.
Combined youthful brain and immune biological aging reduces 17-year mortality by 56%, with brain and immune systems dominating mortality risk prediction more than any combination of the other nine organs studied.
— Oh et al., Nature Medicine (2025)
What this means
Frequently asked questions
Can I get an organ-specific biological aging test today?
Not yet. The plasma proteomics-based 11-organ aging test is available only through Vero Bioscience on a waitlist, with broader availability expected in 2027–2028. Most commercial biological age tests currently use DNA methylation technology, which provides a single composite score rather than organ-specific profiles. If you are interested in participating in research, contact your nearest academic medical center or biotech-affiliated research program.
If my brain aging is “youthful,” does that mean I won’t get Alzheimer’s?
No. Youthful brain biological aging reduces Alzheimer’s risk to a level equivalent to carrying the APOE2/2 protective genotype, but does not eliminate risk. The Stanford study is observational and cannot prove causation. Genetics, lifestyle factors, and other unmeasured variables all influence Alzheimer’s risk. Biological age should be understood as one piece of risk information, not a definitive predictor.
What can I do now to slow brain and immune aging?
The Stanford study does not test interventions, so evidence-based recommendations remain those supported by existing research: consistent sleep (7–9 hours nightly), regular physical exercise (150 minutes weekly moderate activity), social engagement and cognitive stimulation, management of chronic inflammation (through diet, exercise, and treatment of inflammatory conditions), and stress reduction. These are not proven to change biological aging clocks, but they have broad evidence for health benefit. Avoid commercial supplements marketed as “biological age reversal” unless supported by randomized trial data.
The Stanford organ-aging study represents a methodological advance in understanding how aging varies across biological systems, yet translates into clinical action only when combined with evidence that interventions can alter these trajectories. As plasma proteomics-based aging clocks move toward clinical availability, regulatory bodies and medical societies will need to establish interpretation guidelines and appropriate clinical use—distinguishing between research applications and clinical decision-making. In the meantime, the evidence continues to support traditional longevity principles: brain and immune health warrant priority in clinical and personal health strategies.
Source: Stanford organ aging research (Oh et al., Nature Medicine 2025)
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
